ABI Blames ‘Down’ Pharma Market for 9.8-Percent Dip in Fiscal Q1 MS Revenue | GenomeWeb
Applied Biosystems, just off its most significant mass-spectrometry introductions in years, this week announced mass spec revenues dipped 9.8 percent during its fiscal first quarter of 2009 on sluggish sales to pharma companies.
Mass-spec revenues for the three months ended Sept. 30 dropped to $109.2 million from $121.1 million. Sales of the instruments represented 21 percent of the company’s total revenues during the quarter, down from 24 percent of total receipts a year ago.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.